Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.33% and +35.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?